NY State Senate Bill 2023-S7114A

Current Bill Status - Signed by Governor

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Delivered to Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Dec 12, 2024	approval memo.26 signed chap.553
Dec 02, 2024	delivered to governor
May 30, 2024	returned to senate passed assembly ordered to third reading rules cal.165 substituted for a6425a
May 29, 2024	referred to insurance delivered to assembly passed senate
May 22, 2024	advanced to third reading
May 21, 2024	2nd report cal.
May 20, 2024	1st report cal.1254
May 15, 2024	print number 7114a
May 15, 2024	amend and recommit to insurance
Jan 03, 2024	referred to insurance
May 18, 2023	referred to insurance

Votes

- May 29, 2024 - Floor Vote
  S7114A
  
  61
  
  Aye
  
  0
  
  Nay
  
  0
  
  Absent
  
  1
  
  Excused
  
  0
  
  Abstained
  - - Floor Vote: May 29, 2024
      
      aye (61)
      
      Addabbo Jr.
      
      Ashby
      
      Bailey
      
      Borrello
      
      Breslin
      
      Brisport
      
      Brouk
      
      Canzoneri-Fitzpatrick
      
      Chu
      
      Cleare
      
      Comrie
      
      Cooney
      
      Felder
      
      Fernandez
      
      Gallivan
      
      Gianaris
      
      Gonzalez
      
      Gounardes
      
      Griffo
      
      Harckham
      
      Helming
      
      Hinchey
      
      Hoylman-Sigal
      
      Jackson
      
      Kavanagh
      
      Krueger
      
      Lanza
      
      Liu
      
      Mannion
      
      Martinez
      
      Martins
      
      Mattera
      
      May
      
      Mayer
      
      Murray
      
      Myrie
      
      O'Mara
      
      Oberacker
      
      Ortt
      
      Palumbo
      
      Parker
      
      Persaud
      
      Ramos
      
      Rhoads
      
      Rivera
      
      Rolison
      
      Ryan
      
      Salazar
      
      Sanders Jr.
      
      Scarcella-Spanton
      
      Sepúlveda
      
      Serrano
      
      Skoufis
      
      Stavisky
      
      Stec
      
      Stewart-Cousins
      
      Tedisco
      
      Thomas
      
      Webb
      
      Weber
      
      Weik
      
      excused (1)
      
      Walczyk
  May 20, 2024 - Insurance Committee Vote
  S7114A
  
  9
  
  Aye
  
  0
  
  Nay
  
  1
  
  Aye with Reservations
  
  0
  
  Absent
  
  0
  
  Excused
  
  0
  
  Abstained
  - - Insurance Committee Vote: May 20, 2024
      
      aye (9)
      
      Addabbo Jr.
      
      Ashby
      
      Breslin
      
      Cooney
      
      Harckham
      
      Martinez
      
      O'Mara
      
      Sanders Jr.
      
      Scarcella-Spanton
      
      aye wr (1)
      
      Helming

Bill Amendments

Original

A (Active)

co-Sponsors

View additional co-sponsors

2023-S7114 - Details

See Assembly Version of this Bill:: A6425
Law Section:: Insurance Law
Laws Affected:: Amd §§3216, 3221 & 4303, Ins L

2023-S7114 - Summary

Requires health insurance plans to provide coverage for epinephrine auto-injector devices; caps the cost to an insured at $100 per year.

2023-S7114 - Sponsor Memo

                                 
BILL NUMBER: S7114

SPONSOR: RIVERA
 
TITLE OF BILL:

An act to amend the insurance law, in relation to requiring health
insurance plans to provide coverage for epinephrine auto-injector
devices

 
PURPOSE OR GENERAL IDEA OF BILL:

To require insurance coverage for epinephrine auto-injectors ("epipens")
and set an annual cost-sharing cap.

 
SUMMARY OF PROVISIONS:

Section 1 amends subsection (i) of section 3216 of the insurance law, as
it relates to individual accident and health insurance policy
provisions, by adding a new paragraph 39 to require insurance coverage
of epinephrine auto-injectors.

Section 2 amends subsection (k) of section 3221, as it relates to group

or blanket accident and health insurance policies of the insurance law,
by adding a new paragraph 23 that provides coverage requirements and a
maximum copayment of $100 annually for two epinephrine auto-injector
devices.

Section 3 amends section 4303 of the insurance law by adding a new
subsection (vv) to provide coverage requirements and maximum copayment.

Section 4 provides the effective date.

 
JUSTIFICATION:

The rising cost of an epinephrine auto-injector, or "epi-pen," has far
outpaced inflation in recent years. Without mandated coverage and a
reasonable cost-sharing cap, the accessibility of these life-saving
devices are beyond the means of millions of New Yorkers.

In 2010, the most common price for a two-pack of epi-pens was approxi-
mately $100. Today, the generic version will almost always cost upwards
of $350 and the brand name can cost upwards of $700. It is unacceptable
that so many people are forced to risk not having the device during a
life-threatening emergency due to the prohibitive cost.

Separate studies by the National Institutes of Health (NIH) and Blue
Cross Blue Shield showed that emergency room visits by children having
serious anaphylactic reactions have more than doubled during the 2010s,
the same timeframe during which epi-pen prices began to skyrocket. An
epinephrine auto-injector significantly mitigates the risk of death from
a serious allergic reaction.

By mandating insurance plans to provide coverage for epi-pens and
capping the annual cost at $100 for two pens, these life-saving devices
will be more widely accessible for those who need them.  Access to
essential medication should not be contingent on income level.

 
PRIOR LEGISLATIVE HISTORY:

New Bill.

 
FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS:

None.

 
EFFECTIVE DATE:
Immediately

2023-S7114 - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   7114
 
                        2023-2024 Regular Sessions
 
                             I N  S E N A T E
 
                               May 18, 2023
                                ___________
 
 Introduced  by  Sen.  RIVERA -- read twice and ordered printed, and when
   printed to be committed to the Committee on Insurance
 
 AN ACT to amend the insurance  law,  in  relation  to  requiring  health
   insurance  plans  to  provide  coverage  for epinephrine auto-injector
   devices

   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Subsection  (i)  of  section 3216 of the insurance law is
 amended by adding a new paragraph 39 to read as follows:
   (39) EVERY INSURER ISSUING A POLICY OF ACCIDENT AND  HEALTH  INSURANCE
 DELIVERED  OR  ISSUED  FOR  DELIVERY  IN THIS STATE WHICH PROVIDES MAJOR
 MEDICAL OR SIMILAR COMPREHENSIVE-TYPE COVERAGE  SHALL  INCLUDE  COVERAGE
 FOR  TWO  MEDICALLY  NECESSARY EPINEPHRINE AUTO-INJECTOR DEVICES FOR THE
 EMERGENCY TREATMENT OF LIFE-THREATENING ALLERGIC REACTIONS.  SUCH COVER-
 AGE MAY BE SUBJECT TO ANNUAL DEDUCTIBLES AND  COINSURANCE    AS  MAY  BE
 DEEMED  APPROPRIATE  BY  THE  SUPERINTENDENT  AND AS ARE CONSISTENT WITH
 THOSE  ESTABLISHED FOR OTHER BENEFITS WITHIN A  GIVEN  POLICY;  PROVIDED
 HOWEVER,  THE TOTAL AMOUNT THAT A COVERED PERSON IS REQUIRED TO PAY OUT-
 OF-POCKET FOR SUCH DEVICES SHALL BE CAPPED AT AN AMOUNT  NOT  TO  EXCEED
 ONE  HUNDRED  DOLLARS ANNUALLY REGARDLESS   OF THE INSURED'S DEDUCTIBLE,
 COPAYMENT, COINSURANCE OR ANY OTHER COST-SHARING  REQUIREMENT.  FOR  THE
 PURPOSES  OF  THIS  PARAGRAPH,  "EPINEPHRINE AUTO-INJECTOR DEVICE" SHALL
 HAVE THE SAME MEANING AS PROVIDED IN PARAGRAPH (B) OF SUBDIVISION ONE OF
 SECTION THREE THOUSAND-C OF THE PUBLIC HEALTH LAW.
   § 2. Subsection (k) of section 3221 of the insurance law is amended by
 adding a new paragraph 23 to read as follows:
   (23) EVERY GROUP OR BLANKET POLICY OF ACCIDENT  AND  HEALTH  INSURANCE
 DELIVERED  OR  ISSUED  FOR DELIVERY IN THIS STATE WHICH PROVIDES MEDICAL
 COVERAGE THAT INCLUDES COVERAGE FOR PHYSICIAN SERVICES IN A  PHYSICIAN'S
 OFFICE  AND EVERY POLICY WHICH PROVIDES MAJOR MEDICAL OR SIMILAR COMPRE-
 HENSIVE-TYPE  COVERAGE SHALL PROVIDE COVERAGE FOR TWO  MEDICALLY  NECES-
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD10597-01-3

 S. 7114                             2
 
 SARY  EPINEPHRINE  AUTO-INJECTOR  DEVICES FOR THE EMERGENCY TREATMENT OF
 LIFE-THREATENING ALLERGIC REACTIONS.  SUCH COVERAGE MAY  BE  SUBJECT  TO
 ANNUAL  DEDUCTIBLES  AND COINSURANCE AS MAY BE DEEMED APPROPRIATE BY THE
 SUPERINTENDENT  AND  AS ARE CONSISTENT WITH THOSE  ESTABLISHED FOR OTHER
 BENEFITS WITHIN A GIVEN POLICY; PROVIDED HOWEVER, THE TOTAL AMOUNT  THAT
 A COVERED PERSON IS REQUIRED TO PAY OUT-OF-POCKET FOR SUCH DEVICES SHALL
 BE  CAPPED  AT  AN  AMOUNT  NOT  TO  EXCEED ONE HUNDRED DOLLARS ANNUALLY
 REGARDLESS  OF THE INSURED'S DEDUCTIBLE, COPAYMENT, COINSURANCE  OR  ANY
 OTHER  COST-SHARING  REQUIREMENT.    FOR THE PURPOSES OF THIS PARAGRAPH,
 "EPINEPHRINE AUTO-INJECTOR  DEVICE"  SHALL  HAVE  THE  SAME  MEANING  AS
 PROVIDED IN PARAGRAPH (B) OF SUBDIVISION ONE OF SECTION THREE THOUSAND-C
 OF THE PUBLIC HEALTH LAW.
   §  3.  Section  4303  of  the insurance law is amended by adding a new
 subsection (vv) to read as follows:
   (VV) EVERY MEDICAL EXPENSE  INDEMNITY  CORPORATION,  HOSPITAL  SERVICE
 CORPORATION AND HEALTH SERVICE CORPORATION WHICH PROVIDES MEDICAL COVER-
 AGE  THAT  INCLUDES  COVERAGE  FOR  PHYSICIAN  SERVICES IN A PHYSICIAN'S
 OFFICE AND EVERY POLICY WHICH PROVIDES MAJOR MEDICAL OR SIMILAR  COMPRE-
 HENSIVE-TYPE COVERAGE SHALL PROVIDE COVERAGE FOR TWO MEDICALLY NECESSARY
 EPINEPHRINE  AUTO-INJECTOR  DEVICES FOR THE EMERGENCY TREATMENT OF LIFE-
 THREATENING ALLERGIC REACTIONS.  SUCH COVERAGE MAY BE SUBJECT TO  ANNUAL
 DEDUCTIBLES  AND COINSURANCE  AS MAY BE DEEMED APPROPRIATE BY THE SUPER-
 INTENDENT AND AS ARE CONSISTENT WITH THOSE ESTABLISHED FOR  OTHER  BENE-
 FITS  WITHIN  A  GIVEN POLICY; PROVIDED HOWEVER, THE TOTAL AMOUNT THAT A
 COVERED PERSON IS REQUIRED TO PAY OUT-OF-POCKET FOR SUCH  DEVICES  SHALL
 BE  CAPPED  AT  AN  AMOUNT  NOT  TO  EXCEED ONE HUNDRED DOLLARS ANNUALLY
 REGARDLESS  OF THE INSURED'S DEDUCTIBLE, COPAYMENT, COINSURANCE  OR  ANY
 OTHER  COST-SHARING  REQUIREMENT.  FOR  THE PURPOSES OF THIS SUBSECTION,
 "EPINEPHRINE AUTO-INJECTOR  DEVICE"  SHALL  HAVE  THE  SAME  MEANING  AS
 PROVIDED IN PARAGRAPH (B) OF SUBDIVISION ONE OF SECTION THREE THOUSAND-C
 OF THE PUBLIC HEALTH LAW.
   §  4.  This  act shall take effect on the ninetieth day after it shall
 have become a law, and shall apply to any contract or renewal or  exten-
 sion of contract dated after this act shall have become a law.

co-Sponsors

View additional co-sponsors

2023-S7114A (ACTIVE) - Details

See Assembly Version of this Bill:: A6425
Law Section:: Insurance Law
Laws Affected:: Amd §§3216, 3221 & 4303, Ins L

2023-S7114A (ACTIVE) - Summary

Requires health insurance plans to provide coverage for epinephrine auto-injector devices; caps the cost to an insured at $100 per year.

2023-S7114A (ACTIVE) - Sponsor Memo

                                 
BILL NUMBER: S7114A

SPONSOR: RIVERA
 
TITLE OF BILL:

An act to amend the insurance law, in relation to requiring health
insurance plans to provide coverage for epinephrine auto-injector
devices

 
PURPOSE OR GENERAL IDEA OF BILL:

To require insurance coverage for epinephrine auto-injectors ("epipens")
and set an annual cost-sharing cap.

 
SUMMARY OF PROVISIONS:

Section 1 amends subsection (i) of section 3216 of the insurance law, as
it relates to individual accident and health insurance policy
provisions, by adding a new paragraph 39 to require insurance coverage
of epinephrine auto-injectors. The language includes an exemption for
certain high deductible plans to comply with federal law.

Section 2 amends subsection (k) of section 3221, as it relates to group
or blanket accident and health insurance policies of the insurance law,
by adding a new paragraph 23 that provides coverage requirements and a
maximum copayment of $100 annually for two epinephrine auto-injector
devices. The language includes an exemption for certain high deductible
plans to comply with federal law.

Section 3 amends section 4303 of the insurance law by adding a new
subsection (vv) to provide coverage requirements and maximum copayment.
The language includes an exemption for certain high deductible plans to
comply with federal law.

Section 4 provides the effective date.

 
JUSTIFICATION:

The rising cost of an epinephrine auto-injector, or "epi-pen," has far
outpaced inflation in recent years. Without mandated coverage and a
reasonable cost-sharing cap, the accessibility of these life-saving
devices are beyond the means of millions of New Yorkers.

In 2010, the most common price for a two-pack of epi-pens was approxi-
mately $100. Today, the generic version will almost always cost upwards
of $350 and the brand name can cost upwards of $700. It is unacceptable
that so many people are forced to risk not having the device during a
life-threatening emergency due to the prohibitive cost.

Separate studies by the National Institutes of Health (NIH) and Blue
Cross Blue Shield showed that emergency room visits by children having
serious anaphylactic reactions have more than doubled during the 2010s,
the same timeframe during which epi-pen prices began to skyrocket. An
epinephrine auto-injector significantly mitigates the risk of death from
a serious allergic reaction.

By mandating insurance plans to provide coverage for epi-pens and
capping the annual cost at $100 for two pens, these life-saving devices

will be more widely accessible for those who need them.  Access to
essential medication should not be contingent on income level.

 
PRIOR LEGISLATIVE HISTORY:

New Bill.

 
FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS:

None.

 
EFFECTIVE DATE:
Immediately

2023-S7114A (ACTIVE) - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  7114--A
 
                        2023-2024 Regular Sessions
 
                             I N  S E N A T E
 
                               May 18, 2023
                                ___________
 
 Introduced  by  Sens. RIVERA, CLEARE, COONEY, GOUNARDES, HARCKHAM, JACK-
   SON, WEBB -- read twice and ordered printed, and when  printed  to  be
   committed  to the Committee on Insurance -- recommitted to the Commit-
   tee on Insurance in accordance with Senate Rule 6, sec. 8 -- committee
   discharged, bill amended, ordered reprinted as amended and recommitted
   to said committee
 
 AN ACT to amend the insurance  law,  in  relation  to  requiring  health
   insurance  plans  to  provide  coverage  for epinephrine auto-injector
   devices
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Subsection  (i)  of  section 3216 of the insurance law is
 amended by adding a new paragraph 39 to read as follows:
   (39) (A) EVERY INSURER ISSUING A POLICY OF ACCIDENT AND HEALTH  INSUR-
 ANCE DELIVERED OR ISSUED FOR DELIVERY IN THIS STATE WHICH PROVIDES MAJOR
 MEDICAL  OR  SIMILAR  COMPREHENSIVE-TYPE COVERAGE SHALL INCLUDE COVERAGE
 FOR, AT A MINIMUM, TWO  MEDICALLY  NECESSARY  EPINEPHRINE  AUTO-INJECTOR
 DEVICES   FOR  THE  EMERGENCY  TREATMENT  OF  LIFE-THREATENING  ALLERGIC
 REACTIONS.  SUCH COVERAGE MAY BE SUBJECT TO ANNUAL DEDUCTIBLES AND COIN-
 SURANCE  AS MAY BE DEEMED APPROPRIATE BY THE SUPERINTENDENT AND  AS  ARE
 CONSISTENT  WITH  THOSE    ESTABLISHED FOR OTHER BENEFITS WITHIN A GIVEN
 POLICY; PROVIDED  HOWEVER, THE TOTAL AMOUNT THAT  A  COVERED  PERSON  IS
 REQUIRED  TO  PAY  OUT-OF-POCKET  FOR SUCH DEVICES SHALL BE CAPPED AT AN
 AMOUNT NOT TO EXCEED ONE HUNDRED DOLLARS ANNUALLY  REGARDLESS    OF  THE
 INSURED'S  DEDUCTIBLE,  COPAYMENT, COINSURANCE OR ANY OTHER COST-SHARING
 REQUIREMENT.  IF UNDER  FEDERAL  LAW,  APPLICATION  OF  THIS REQUIREMENT
 WOULD  RESULT IN HEALTH SAVINGS ACCOUNT INELIGIBILITY UNDER    26    USC
 223,    THIS  REQUIREMENT   SHALL     APPLY     FOR    HEALTH    SAVINGS
 ACCOUNT-QUALIFIED HIGH  DEDUCTIBLE  HEALTH  PLANS  WITH  RESPECT TO  THE
 DEDUCTIBLE OF SUCH A PLAN AFTER THE ENROLLEE HAS SATISFIED  THE  MINIMUM
 DEDUCTIBLE   UNDER 26  USC  223,  EXCEPT  FOR  WITH  RESPECT TO ITEMS OR
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD10597-03-4

 S. 7114--A                          2
 
 SERVICES THAT ARE PREVENTIVE CARE PURSUANT TO 26  USC  223(C)(2)(C),  IN
 WHICH  CASE THE REQUIREMENTS OF THIS PARAGRAPH SHALL APPLY REGARDLESS OF
 WHETHER THE MINIMUM DEDUCTIBLE UNDER 26 USC 223 HAS BEEN SATISFIED.
   (B)  FOR  THE  PURPOSES  OF THIS PARAGRAPH, "EPINEPHRINE AUTO-INJECTOR
 DEVICE" SHALL HAVE THE SAME MEANING AS  PROVIDED  IN  PARAGRAPH  (B)  OF
 SUBDIVISION ONE OF SECTION THREE THOUSAND-C OF THE PUBLIC HEALTH LAW.
   § 2. Subsection (k) of section 3221 of the insurance law is amended by
 adding a new paragraph 23 to read as follows:
   (23)  (A)  EVERY GROUP OR BLANKET POLICY OF ACCIDENT AND HEALTH INSUR-
 ANCE DELIVERED OR ISSUED FOR  DELIVERY  IN  THIS  STATE  WHICH  PROVIDES
 MEDICAL  COVERAGE  THAT  INCLUDES  COVERAGE  FOR PHYSICIAN SERVICES IN A
 PHYSICIAN'S OFFICE AND EVERY POLICY  WHICH  PROVIDES  MAJOR  MEDICAL  OR
 SIMILAR  COMPREHENSIVE-TYPE    COVERAGE SHALL PROVIDE COVERAGE FOR, AT A
 MINIMUM, TWO MEDICALLY NECESSARY EPINEPHRINE AUTO-INJECTOR  DEVICES  FOR
 THE  EMERGENCY  TREATMENT  OF LIFE-THREATENING ALLERGIC REACTIONS.  SUCH
 COVERAGE MAY BE SUBJECT TO ANNUAL DEDUCTIBLES AND COINSURANCE AS MAY  BE
 DEEMED  APPROPRIATE  BY  THE  SUPERINTENDENT  AND AS ARE CONSISTENT WITH
 THOSE  ESTABLISHED FOR OTHER BENEFITS WITHIN A  GIVEN  POLICY;  PROVIDED
 HOWEVER,  THE TOTAL AMOUNT THAT A COVERED PERSON IS REQUIRED TO PAY OUT-
 OF-POCKET FOR SUCH DEVICES SHALL BE CAPPED AT AN AMOUNT  NOT  TO  EXCEED
 ONE  HUNDRED  DOLLARS ANNUALLY REGARDLESS   OF THE INSURED'S DEDUCTIBLE,
 COPAYMENT, COINSURANCE OR ANY OTHER COST-SHARING REQUIREMENT.  IF  UNDER
 FEDERAL  LAW,  APPLICATION  OF  THIS REQUIREMENT  WOULD RESULT IN HEALTH
 SAVINGS  ACCOUNT  INELIGIBILITY UNDER 26   USC   223,   THIS REQUIREMENT
 SHALL   APPLY   FOR   HEALTH   SAVINGS ACCOUNT-QUALIFIED HIGH    DEDUCT-
 IBLE   HEALTH   PLANS   WITH   RESPECT TO THE  DEDUCTIBLE OF SUCH A PLAN
 AFTER THE ENROLLEE HAS SATISFIED  THE  MINIMUM DEDUCTIBLE  UNDER 26  USC
 223,  EXCEPT  FOR  WITH  RESPECT TO ITEMS OR  SERVICES THAT ARE  PREVEN-
 TIVE  CARE  PURSUANT TO 26   USC   223(C)(2)(C),   IN   WHICH   CASE THE
 REQUIREMENTS OF THIS PARAGRAPH SHALL APPLY REGARDLESS OF    WHETHER  THE
 MINIMUM DEDUCTIBLE UNDER 26 USC 223 HAS BEEN SATISFIED.
   (B)  FOR  THE  PURPOSES  OF THIS PARAGRAPH, "EPINEPHRINE AUTO-INJECTOR
 DEVICE" SHALL HAVE THE SAME MEANING AS  PROVIDED  IN  PARAGRAPH  (B)  OF
 SUBDIVISION ONE OF SECTION THREE THOUSAND-C OF THE PUBLIC HEALTH LAW.
   §  3.  Section  4303  of  the insurance law is amended by adding a new
 subsection (vv) to read as follows:
   (VV) (1) EVERY MEDICAL EXPENSE INDEMNITY CORPORATION, HOSPITAL SERVICE
 CORPORATION AND HEALTH SERVICE CORPORATION WHICH PROVIDES MEDICAL COVER-
 AGE THAT INCLUDES COVERAGE  FOR  PHYSICIAN  SERVICES  IN  A  PHYSICIAN'S
 OFFICE  AND EVERY POLICY WHICH PROVIDES MAJOR MEDICAL OR SIMILAR COMPRE-
 HENSIVE-TYPE COVERAGE SHALL PROVIDE COVERAGE  FOR,  AT  A  MINIMUM,  TWO
 MEDICALLY  NECESSARY EPINEPHRINE AUTO-INJECTOR DEVICES FOR THE EMERGENCY
 TREATMENT OF LIFE-THREATENING ALLERGIC REACTIONS.  SUCH COVERAGE MAY  BE
 SUBJECT  TO  ANNUAL DEDUCTIBLES AND COINSURANCE  AS MAY BE DEEMED APPRO-
 PRIATE BY THE SUPERINTENDENT AND AS ARE  CONSISTENT  WITH  THOSE  ESTAB-
 LISHED  FOR  OTHER BENEFITS WITHIN A GIVEN POLICY; PROVIDED HOWEVER, THE
 TOTAL AMOUNT THAT A COVERED PERSON IS REQUIRED TO PAY OUT-OF-POCKET  FOR
 SUCH  DEVICES  SHALL  BE  CAPPED  AT AN AMOUNT NOT TO EXCEED ONE HUNDRED
 DOLLARS ANNUALLY REGARDLESS   OF THE  INSURED'S  DEDUCTIBLE,  COPAYMENT,
 COINSURANCE  OR  ANY  OTHER COST-SHARING REQUIREMENT.  IF UNDER  FEDERAL
 LAW,  APPLICATION  OF  THIS  REQUIREMENT  WOULD RESULT IN HEALTH SAVINGS
 ACCOUNT INELIGIBILITY UNDER 26   USC   223,   THIS  REQUIREMENT    SHALL
 APPLY     FOR     HEALTH     SAVINGS ACCOUNT-QUALIFIED HIGH   DEDUCTIBLE
 HEALTH  PLANS  WITH  RESPECT TO THE DEDUCTIBLE OF SUCH A PLAN AFTER  THE
 ENROLLEE  HAS SATISFIED   THE   MINIMUM  DEDUCTIBLE  UNDER 26  USC  223,
 EXCEPT  FOR  WITH  RESPECT TO ITEMS OR SERVICES THAT ARE PREVENTIVE CARE
 S. 7114--A                          3
 
 PURSUANT TO 26  USC  223(C)(2)(C), IN WHICH   CASE THE  REQUIREMENTS  OF
 THIS  PARAGRAPH SHALL APPLY REGARDLESS OF WHETHER THE MINIMUM DEDUCTIBLE
 UNDER 26 USC 223 HAS BEEN SATISFIED.
   (2)  FOR  THE  PURPOSES OF THIS SUBSECTION, "EPINEPHRINE AUTO-INJECTOR
 DEVICE" SHALL HAVE THE SAME MEANING AS  PROVIDED  IN  PARAGRAPH  (B)  OF
 SUBDIVISION ONE OF SECTION THREE THOUSAND-C OF THE PUBLIC HEALTH LAW.
   § 4. This act shall take effect January 1, 2026 and shall apply to all
 policies  and contracts issued, renewed, modified, altered or amended on
 or after such date.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Senate Bill S7114A

Sponsored By

Current Bill Status - Signed by Governor

May 29, 2024 - Floor Vote

Floor Vote: May 29, 2024

May 20, 2024 - Insurance Committee Vote

Insurance Committee Vote: May 20, 2024

Bill Amendments

co-Sponsors

2023-S7114 - Details

2023-S7114 - Summary

2023-S7114 - Sponsor Memo

2023-S7114 - Bill Text download pdf

co-Sponsors

2023-S7114A (ACTIVE) - Details

2023-S7114A (ACTIVE) - Summary

2023-S7114A (ACTIVE) - Sponsor Memo

2023-S7114A (ACTIVE) - Bill Text download pdf

Comments

Senate Bill S7114A

Share this bill

Sponsored By

Current Bill Status - Signed by Governor

Bill Amendments

co-Sponsors

2023-S7114 - Details

2023-S7114 - Summary

2023-S7114 - Sponsor Memo

2023-S7114 - Bill Text download pdf

co-Sponsors

2023-S7114A (ACTIVE) - Details

2023-S7114A (ACTIVE) - Summary

2023-S7114A (ACTIVE) - Sponsor Memo

2023-S7114A (ACTIVE) - Bill Text download pdf

Comments